TY - JOUR
T1 - Novel radionuclides for use in Nuclear Medicine in Europe
T2 - where do we stand and where do we go?
AU - Radzina, Maija
AU - Saule, Laura
AU - Mamis, Edgars
AU - Koester, Ulli
AU - Cocolios, Thomas Elias
AU - Pajuste, Elina
AU - Kalnina, Marika
AU - Palskis, Kristaps
AU - Sawitzki, Zoe
AU - Talip, Zeynep
AU - Jensen, Mikael
AU - Duchemin, Charlotte
AU - Leufgen, Kirsten
AU - Stora, Thierry
N1 - Funding Information:
PRISMAP “Production of high purity isotopes by mass separation” is the European medical isotope programme that federates a consortium of key European facilities such as intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical research institutes and hospitals active in the translation of the emerging radionuclides into medical diagnosis and treatment. PRISMAP creates a single-entry point for a fragmented user community distributed amongst universities, research centers, industry and hospitals, in a similar way as how the National Isotope Development Centre NIDC, supported by the Department of Energy (DOE), has provided radionuclide sources for users in the United States of America (USA).
Funding Information:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP). This document reflects only the view of the author(s). The funding agenc(y/ies) is/are not responsible for any use that may be made of the information it contains.
Publisher Copyright:
© 2023, Springer Nature Switzerland AG.
PY - 2023/12
Y1 - 2023/12
N2 - BACKGROUND: In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe.MAIN BODY: A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. A total of 40 preclinical/clinical users institutions took part in the survey. Clinical end users currently use the following radionuclides in their studies:
177Lu,
68 Ga,
111In,
90Y, other alpha emitters,
225Ac,
64Cu and Terbium isotopes. Radionuclides that would be of interest for users within the next 2-5 years are
64Cu, Terbium radionuclide "family" and alpha emitters, such as
225Ac.
CONCLUSIONS: Thanks to a questionnaire distributed by the PRISMAP consortium, the current status and needs of clinical end-users in nuclear medicine were identified.
AB - BACKGROUND: In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe.MAIN BODY: A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. A total of 40 preclinical/clinical users institutions took part in the survey. Clinical end users currently use the following radionuclides in their studies:
177Lu,
68 Ga,
111In,
90Y, other alpha emitters,
225Ac,
64Cu and Terbium isotopes. Radionuclides that would be of interest for users within the next 2-5 years are
64Cu, Terbium radionuclide "family" and alpha emitters, such as
225Ac.
CONCLUSIONS: Thanks to a questionnaire distributed by the PRISMAP consortium, the current status and needs of clinical end-users in nuclear medicine were identified.
KW - Radionuclides
KW - Diagnostic
KW - Therapy
KW - PET/CT
KW - PRISMAP programme
UR - https://www.scopus.com/pages/publications/85173991268
U2 - 10.1186/s41181-023-00211-5
DO - 10.1186/s41181-023-00211-5
M3 - Review article
C2 - 37823964
SN - 2365-421X
VL - 8
JO - EJNMMI Radiopharmacy and Chemistry
JF - EJNMMI Radiopharmacy and Chemistry
IS - 1
M1 - 27
ER -